(MedPage Today) — In cystic fibrosis, vanzacaftor-tezacaftor-deutivacaftor (VTD; Alyftrek) showed great potential for modifying the progression of disease in young children, according to the TIMBERLINE study.
Assessing safety and tolerability…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
